GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lucira Health Inc (OTCPK:LHDXQ) » Definitions » Altman Z2-Score

Lucira Health (Lucira Health) Altman Z2-Score : -7.75 (As of May. 15, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Lucira Health Altman Z2-Score?

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Warning Sign:

Lucira Health has a Altman Z2-Score of -7.75, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Lucira Health's Altman Z2-Score or its related term are showing as below:


Lucira Health Altman Z2-Score Historical Data

The historical data trend for Lucira Health's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lucira Health Altman Z2-Score Chart

Lucira Health Annual Data
Trend Dec18 Dec19 Dec20 Dec21
Altman Z2-Score
- - -1.02 4.54

Lucira Health Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.94 4.54 4.18 3.02 -7.75

Competitive Comparison of Lucira Health's Altman Z2-Score

For the Medical Devices subindustry, Lucira Health's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lucira Health's Altman Z2-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lucira Health's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Lucira Health's Altman Z2-Score falls into.



Lucira Health Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Lucira Health's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.2006+3.26*-1.3955+6.72*-0.7464+1.05*0.4746
=-7.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Sep. 2022:
Total Assets was $189.2 Mil.
Total Current Assets was $120.5 Mil.
Total Current Liabilities was $82.5 Mil.
Retained Earnings was $-264.0 Mil.
Pre-Tax Income was -126.848 + -21.934 + 13.337 + -7.798 = $-143.2 Mil.
Interest Expense was -0.949 + -0.826 + -0.537 + 0.278 = $-2.0 Mil.
Total Liabilities was $128.3 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(120.471 - 82.521)/189.185
=0.2006

X2=Retained Earnings/Total Assets
=-264.002/189.185
=-1.3955

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-143.243 - -2.034)/189.185
=-0.7464

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(60.889 - 0)/128.296
=0.4746

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Lucira Health has a Altman Z2-Score of -7.75 indicating it is in Distress Zones.


Lucira Health  (OTCPK:LHDXQ) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Lucira Health Altman Z2-Score Related Terms

Thank you for viewing the detailed overview of Lucira Health's Altman Z2-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Lucira Health (Lucira Health) Business Description

Traded in Other Exchanges
N/A
Address
1412 62nd Street, Emeryville, CA, USA, 94608
Lucira Health Inc is a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits. It has developed a testing platform that produces high-complexity-laboratory-accurate molecular testing in a single-use and user-friendly test kit that is powered by two AA batteries and fit in the palm of a hand. The company's initial focus is within respiratory diseases, and initially for COVID-19 and influenza Types A and B indications.
Executives
Anthony Joseph Allen officer: Chief Operations Officer 1412 62ND STREET, EMERYVILLE CA 94608
Epq Llc, Lcovd Safe Ps other: Less than 10% owner 9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Chad Boeding other: CEO of 10% owner ONE LOMBARD STREET, SUITE 200, SAN FRANCISCO CA 94111
Epiq Capital Group, Llc 10 percent owner ONE LOMBARD STREET, SUITE 200, SAN FRANCISCO CA 94111
Epq Llc, Lcovd Ps 10 percent owner 9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Epq Llc, Lflu Ps other: Less than 10% owner 9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Epq Llc, Ltest Ps other: Less than 10% Owner 9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Richard Clavano Narido officer: Interim CFO 12 HANSEN CT, MORAGA CA 94556
Ghazi Kashmolah officer: Ex. VP &Chief Quality Officer 1412 62ND STREET, EMERYVILLE CA 94608
Kevin Walter Collins officer: Chief Revenue Officer C/O LUCIRA HEALTH, INC., 1412 62ND STREET, EMERYVILLE CA 94608
Dan George officer: CFO and Treasurer 1412 62ND STREET, EMERYVILLE CA 94608
Erik T. Engelson director, officer: President and Chief Executive 1412 62ND STREET, EMERYVILLE CA 94608
Debkishore Mitra director, officer: Chief Technology Officer 1412 62ND STREET, EMERYVILLE CA 94608
Tamanna Prashar officer: Vice President 1412 62ND STREET, EMERYVILLE CA 94608
Alison Mccauley director C/O LUCIRA HEALTH, INC., 1412 62ND STREET, EMERYVILLE CA 94608